Company: PTPI
Filing Date: 2025-02-13
Form Type: CORRESP
Source: 0001104659-25-012630
Chunk: 0

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: CORRESP
Chunk 0
---
<div align='center'>Petros Pharmaceuticals, Inc.
1185 Avenue of the Americas, 3rd Floor

New York, NY 10036</div>

February 13, 2025

VIA EDGAR

Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
Washington, D.C. 20549
Attention: Daniel Crawford

| Re: | Petros Pharmaceuticals, Inc.                                          
 Amendment No. 1 to the Registration Statement on Form S-1/A           
 Originally filed on January 24, 2025, as amended on February 10, 2025 
 File No. 333-284495 (as amended, the “Registration Statement”)        |

Dear Mr. Crawford:

On behalf of Petros Pharmaceuticals,
Inc. (the “Company”), we hereby transmit the Company’s response to the comment letter received from the
staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”),
dated February 12, 2025, regarding the Registration Statement. This letter is being submitted together with the Company’s Amendment No. 2 to the Registration Statement, filed on February 13,
2025. For the Staff’s convenience, we have repeated below the Staff’s
comment in bold, and have followed the comment with the Company’s response.

| 1. | We note your disclosure indicates that you have an "alternative cashless exercise option."                                                     
 Based on your disclosures on page 59 it appears that each Series B Warrant could be exercised for 3 common stock shares on a cashless          
 basis rather than for one share on a cash basis. Accordingly, please revise the prospectus to disclose, if true, that you are offering         
 up to 371,747,210 shares of common stock underlying the Series B Warrants rather than 223,048,326 shares. Also highlight that the “alternative 
 cashless exercise” provision would allow a warrant holder to receive 3 shares of common stock without having to make any exercise              
 payment. Explain that as a result you do not expect to receive any cash proceeds from the exercise of the Warrants because, if true, it        
 is highly unlikely that a warrant holder would wish to pay an exercise price to receive one share when they could choose the alternative       
 cashless exercise option and pay no money to receive 3 shares.                                                                                 |

The Company respectfully acknowledges
the Staff’s comment and advises the Staff that the Series A Warrants and the Series B W